Phase 2 N=2 A Phase I/II Study of KDX-0811(Dexrazoxane) in the Treatment of Accidental Extravasation of Anthracycline Anti-cancer Agents
Extravasations of Anthracycline Anti-cancer Agents
Primary: Adverse Events — 2 participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=54 Natriuretic Peptide Concentrations of B-type (BNP) During Anesthesia in Patients Previously Sensitized to Anthracyclines
Breast Cancer
Primary: Pre-operative Concentration of NT-proBNP — 38.9; 32.2 pg/ml — p=0.714
N/A N=133 Patterns and Prevalence of FDG Extravasation in PET/CT Scans
Intravenous Infiltration
Primary: Number of Participants With Intraveneous Infiltration of FDG During Routine PET/CT Imaging by Visually Assessment of Interpreting Physicians — 17; 32 Participants
Phase 2 N=102 Doxorubicin HCI Liposome Injection Versus Weekly Docetaxel in Patients First Relapse Metastatic Breast Cancer
Breast Cancer
Primary: Overall Response Rate (ORR), the Percentage of Patients Who Experience an Objective Benefit From Treatment — 28; 31 percentage of patients
N/A N=1,972 Application Of Epirubicin Within A Neo-/Adjuvant Chemotherapy In Patients With Primary Breast Cancer
Breast Neoplasm
Primary: Percentage of Participants With Disease Free Survival (DFS) — 83.7 Percentage of participants
Phase 1 N=25 Prevention of Heart Failure Induced by Doxorubicin With Early Administration of Dexrazoxane
Degradation of Top2b and Top2a in Human by Dexrazoxane · Time Course and Degradation of Top2b in Human by Dexrazoxane · Effects of Dexrazoxane on Healthy Human
Primary: Participants With 95% Reduction in Topoisomerase 2 b From Baseline — 0; 0; 0; 0 Participants
Phase 2 N=182 Carvedilol in Preventing Heart Failure in Childhood Cancer Survivors
Hematopoietic and Lymphoid Cell Neoplasm · Malignant Solid Neoplasm
Primary: Average Left-Ventricular Wall Thickness-Dimension Ratio Z-score (LVWT/Dz) — -0.1372; -0.0893; -0.2167; 0.3215 z-score — p=0.15
Phase 2 N=3 Doxorubicin Hydrochloride Liposome, Cyclophosphamide, and Trastuzumab in Treating Patients With Stage IV Breast Cancer
HER2-positive Breast Cancer · Male Breast Cancer · Recurrent Breast Cancer
Primary: Maximum Tolerated Dose and Optimal Tolerated Dose of Pegylated Liposomal Doxorubicin Hydrochloride (Doxil) When Given in Combination With Cyclophosphamide (Phase I) — 30…
Phase 1 N=30 Pharmacokinetics of Doxorubicin in cTACE of Liver Cancer
Liver Cancer
Primary: Pharmacokinetics Profile-- Peak of Plasma Concentration (Dose-normalized) — 2.67; 3.68; 7.11; 0.08 ng/mL/mg — p=.036
Phase 2 N=2 Doxorubicin HCL Liposome Injection (DOXIL) in Combination With Abraxane in Patients With Metastatic Breast Cancer
Metastatic Breast Cancer
Primary: This Trial Will Use DOXIL and Abraxane as First or Second Line Chemotherapy in Patients With a Diagnosis of Metastatic Breast Cancer (MBC).
Phase 2 N=46 Chemoembolisation of Hepatocellular Carcinomas Not Subject to Interventive Care by Idarubicin-loaded Beads - IDASPHERE II
Liver Cancer
Primary: Number of Participants With Complete Response or Partial Response (Objective Response), as Assessed According Central Review — 22; 22 Participants
N/A N=60 Echocardiographic Changes During Adjuvant Therapy in Hispanic Women With Her-2 Neu Expressing Breast Cancer
Breast Cancer
Primary: LVEF — 65.4; 64.7; 62.2 percentage of blood in left ventricle — p=<0.0005
Phase 2 N=279 Preventing Anthracycline Cardiovascular Toxicity With Statins (PREVENT)
Breast Cancer · Lymphoma
Primary: Left Ventricular Ejection Fraction (LVEF) — 58.1; 57.9 percent ejected from LV per heartbeat — p=0.84
Phase 1 N=27 Acute Exercise Cardioprotection From Doxorubicin
Breast Cancer
Primary: Global Longitudinal Strain — 19.2; -19.6; 21.4; -21.5 % deformation
Phase 1 N=15 T-DM1 and Non-pegylated Liposomal Doxorubicin in Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Metastatic Breast Cancer
Breast Cancer
Primary: Hematological - Dose Limiting Toxicities — 1; 3; 7; 1 participants
Phase 2 N=181 Phase II Trial to Compare the Safety of Two Chemotherapy Plus Trastuzumab Regimens as Adjuvant Therapy for HER2-positive Breast Cancer (Study P05048)
Breast Neoplasm
Primary: Number of Participants Who Experienced Cardiac Events (Level 1 or 2), or Inability to Administer Trastuzumab Either During the 8 Cycles of Chemotherapy or According to…
N/A N=107 Pharmacokinetics of Daunorubicin in Young Patients With Cancer
Unspecified Childhood Solid Tumor, Protocol Specific
Primary: Population Estimates for Daunorubicin Hydrochloride Clearance — 116 L/m2/hr
Phase 2 N=126 Combination Therapy With MYOCET® (Doxorubicin HCL Liposome for Injection) in Participants With HER2-Positive Breast Cancer
Breast Cancer
Primary: Percentage of Participants Exhibiting a Pathological Complete Response (pCR) in Breast — 41.3; 54.0 percentage of participants — p=0.154
Phase 2 N=300 STOP-CA (Statins TO Prevent the Cardiotoxicity From Anthracyclines)
Heart Failure
Primary: The Percentage of Individuals in Each Group With a Significant Decline in the LVEF. — 22; 9 Participants
Phase 2 N=104 Preoperative Dose-dense Doxorubicin and Cyclophosphamide Followed by Paclitaxel With Bevacizumab in Operable Breast Cancer
Breast Cancer
Primary: Pathologic Complete Response Rate After Preoperative Therapy in This Patient Population. — 8; 44 percentage of participants
Phase 2 N=78 Trial of Amrubicin as Treatment for Patients With HER2-Negative Metastatic Breast Cancer
Metastatic Breast Cancer
Primary: Progression-Free Survival (PFS) of MTD/Phase II Patients — 4.0 months
Phase 2 N=11 Carvedilol for the Prevention of Anthracycline/Anti-HER2 Therapy Associated Cardiotoxicity Among Women With HER2-Positive Breast Cancer Using Myocardial Strain Imaging for Early Risk Stratification
Breast Cancer
Primary: Maximum Change in LVEF at 3 Months — 1; -5 change in percent ejection fraction
Phase 2 N=73 Doxorubicin With Upfront Dexrazoxane for the Treatment of Advanced or Metastatic Soft Tissue Sarcoma
Sarcoma, Soft Tissue · Soft Tissue Sarcoma · Undifferentiated Pleomorphic Sarcoma
Primary: Progression-free Survival (PFS) (Arm 1 Only) — 5.48 months
N/A N=20 Chemoembolization Using Doxorubicin in Treating Patients With Liver Cancer That Cannot Be Removed By Surgery
Liver Cancer
Primary: Safety — 16; 3 Participants
N/A N=280 Evaluation of Cryoprotection Induced Nail Toxicity Docetaxel Low Cumulative Dose
Breast Neoplasms
Primary: Evaluation of the Occurrence of Nail Toxicity of Grade 2 of Common Toxicity Criteria for Adverse Effects V4.0 Evaluated at 8 Weeks Post Infusion of Docetaxel. — 26; 49…
Phase 1 N=20 Liposomal Doxorubicin Before Mastectomy in Treating Women With Invasive Breast Cancer
Breast Cancer
Primary: Maximum Tolerated Dose (MTD) — 10 milligrams
N/A N=19 Enalapril Maleate and Doxorubicin Hydrochloride in Treating Women With Breast Cancer
Breast Cancer
Primary: Number of Patients With Doxorubicin Plasma Concentrations Demonstrating a Significant Increase or Decrease When Doxorubicin Was Given With Enalapril as Compared to When…
Phase 2 N=49 Caelyx, Cyclophosphamide and Herceptin in Patients With Metastatic Breast Cancer
Breast Cancer
Primary: Objective Response Rate (ORR) — 33 Participants
Phase 2 N=7 Study of Liposomal Annamycin for the Treatment of Subjects With Acute Myeloid Leukemia (AML)
Leukemia, Myeloid, Acute
Primary: Dose-limiting Toxicity — 0; 0 Participants
Phase 2 N=32 Therapy for Locally Advanced Breast Cancer Using Doxil, Paclitaxel, and Cyclophosphamide With Avastin
Invasive Breast Cancer
Primary: Rate of Achievement of Pathological Complete Response (pCR) — 9 pathology specimens from participants